JP2025503721A5 - - Google Patents
Info
- Publication number
- JP2025503721A5 JP2025503721A5 JP2024542127A JP2024542127A JP2025503721A5 JP 2025503721 A5 JP2025503721 A5 JP 2025503721A5 JP 2024542127 A JP2024542127 A JP 2024542127A JP 2024542127 A JP2024542127 A JP 2024542127A JP 2025503721 A5 JP2025503721 A5 JP 2025503721A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- orthopoxvirus
- promoter element
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151830.1 | 2022-01-17 | ||
| EP22151830 | 2022-01-17 | ||
| PCT/EP2023/050917 WO2023135313A1 (en) | 2022-01-17 | 2023-01-17 | Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503721A JP2025503721A (ja) | 2025-02-04 |
| JP2025503721A5 true JP2025503721A5 (enExample) | 2026-01-20 |
Family
ID=80222249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542127A Pending JP2025503721A (ja) | 2022-01-17 | 2023-01-17 | がん治療用免疫刺激タンパク質をコードする組換えオルソポックスウイルスベクター |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250115928A1 (enExample) |
| EP (1) | EP4466286A1 (enExample) |
| JP (1) | JP2025503721A (enExample) |
| KR (1) | KR20240134204A (enExample) |
| CN (1) | CN118556081A (enExample) |
| AU (1) | AU2023207821A1 (enExample) |
| CA (1) | CA3248326A1 (enExample) |
| IL (1) | IL314357A (enExample) |
| MX (1) | MX2024008847A (enExample) |
| WO (1) | WO2023135313A1 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2415783B1 (en) * | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| SG11202006457YA (en) * | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| CN113454231A (zh) * | 2018-12-21 | 2021-09-28 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
-
2023
- 2023-01-17 CA CA3248326A patent/CA3248326A1/en active Pending
- 2023-01-17 AU AU2023207821A patent/AU2023207821A1/en active Pending
- 2023-01-17 KR KR1020247027409A patent/KR20240134204A/ko active Pending
- 2023-01-17 EP EP23701030.1A patent/EP4466286A1/en active Pending
- 2023-01-17 MX MX2024008847A patent/MX2024008847A/es unknown
- 2023-01-17 IL IL314357A patent/IL314357A/en unknown
- 2023-01-17 WO PCT/EP2023/050917 patent/WO2023135313A1/en not_active Ceased
- 2023-01-17 CN CN202380017413.8A patent/CN118556081A/zh active Pending
- 2023-01-17 JP JP2024542127A patent/JP2025503721A/ja active Pending
- 2023-01-17 US US18/729,271 patent/US20250115928A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514420A5 (enExample) | ||
| JP2557053B2 (ja) | 腫瘍壊死因子の精製、製造および使用法 | |
| US20240294883A1 (en) | Compositions for producing recombinant virus | |
| AU616873B2 (en) | Horse gamma-interferon | |
| JP7301748B2 (ja) | 複数トランスジーン組み換えアデノウイルス | |
| FR2583429A1 (fr) | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u | |
| JP2022541520A5 (enExample) | ||
| Sano et al. | Expression vectors for streptavidin-containing chimeric proteins | |
| JP2023527083A5 (enExample) | ||
| FI4536686T3 (fi) | Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi | |
| JP2007508036A (ja) | 肝細胞癌特異的プロモーターおよびその使用 | |
| JPH06181771A (ja) | 新規なヒトｉ型インターフェロン | |
| WO2020072371A1 (en) | Melanoma canine vaccine compositions and methods of use thereof | |
| CN115989321B (zh) | 病毒制剂、用于配制病毒制剂的溶液及其用途 | |
| CN116478932A (zh) | 基因修饰的免疫细胞及其应用 | |
| CN118813547A (zh) | 一种双基因修饰的car-t细胞及其应用 | |
| RU2024114971A (ru) | Рекомбинантный вирусный вектор orthopox, кодирующий иммуностимулирующие белки, для лечения рака | |
| Shigekane et al. | The bi-directional transcriptional promoters for the latency-relating transcripts of the pp38/pp24 mRNAs and the 1.8 kb-mRNA in the long inverted repeats of Marek’s disease virus serotype 1 DNA are regulated by common promoter-specific enhancers | |
| CN117229413A (zh) | 一种针对SFTSV-Gn和CD3的双特异性抗体及其制备方法 | |
| JP2023540052A5 (enExample) | ||
| US20250115928A1 (en) | Recombinant Orthopox Viral Vector Encoding Immunostimulatory Proteins for Cancer Treatment | |
| AU2003225141A1 (en) | Alternatively spliced nucleic acid molecules | |
| JPS6091984A (ja) | 新規プラスミドベクタ− | |
| WO2025161993A1 (zh) | 具有双重肿瘤靶向性的重组溶瘤腺病毒、其制备方法及其应用 | |
| CN104073498B (zh) | 大肠杆菌外膜蛋白TolC核酸适配体的序列及用途 |